Evidence map›Paper›PMID 42004942›Full record

ReviewNanoscale advances2026

Antimicrobial nanomaterials at the nanoscale: design principles, mechanisms, and global challenges.

Dinithi Senanayake, Imalka Munaweera

Abstract readReview
In one paragraph

Review in Nanoscale advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Dinithi SenanayakeDepartment of Chemistry, Faculty of Applied Sciences, University of Sri Jayewardenepura Sri Lanka imalka@sjp.ac.lk.ORCID https://orcid.org/0009-0008-1551-836X
Imalka MunaweeraDepartment of Chemistry, Faculty of Applied Sciences, University of Sri Jayewardenepura Sri Lanka imalka@sjp.ac.lk.ORCID https://orcid.org/0000-0002-0665-1563

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The rapid escalation of antimicrobial resistance (AMR) represents a major global health challenge, undermining the clinical efficacy of conventional antibiotics and driving the demand for alternative therapeutic strategies. Advances in nanoscience have positioned nanoscale materials as a powerful platform for the development of next generation antimicrobial systems, owing to their precisely tunable physicochemical features and ability to operate through multiple resistance evasive modes of action. This review provides a comprehensive overview of recent progress in antimicrobial nanomaterials, encompassing metallic and metal oxide nanoparticles, polymeric and carbon based nanostructures, as well as multifunctional hybrid architectures. Key antimicrobial mechanisms, including controlled ion release, reactive oxygen species generation, membrane perturbation, and synergistic chemical and physical interactions at the nano bio interface, are critically discussed. Particular attention is given to the growing class of stimuli responsive and smart nanomaterials that enable spatiotemporal activation, enhanced targeting, and improved therapeutic precision. The integration of antimicrobial functionality with anti-inflammatory, regenerative, and diagnostic capabilities highlights the versatility of nanoscale systems for biomedical applications such as wound management, implant surface engineering, biofilm mitigation, and targeted drug delivery. Despite significant advances, challenges related to cytocompatibility, biodegradability, scalable manufacturing, and regulatory harmonization remain. Finally, emerging directions including nanozymes, metal organic frameworks, artificial intelligence assisted material design, and antimicrobial 3D printed nanocomposites are discussed, underscoring the pivotal role of nanoscale innovation in addressing AMR and advancing future antimicrobial technologies.

Identifiers

PMID42004942
PMCPMC13088907

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.